Drug Formulation & Bioavailability Congress September 05-07, 2016 Beijing, China

Anand has over 14 years of research experience in the pharmaceutical industry including generics and New Chemical Entities (NCE) development, scale up, technology transfer, registration, where he was involved in the overall end to end project management. He is currently working as a Director and Head of Formulation Development at BioDuro and supporting Yangtze River Pharmaceutical Group for formulation related technologies. Prior to joining BioDuro Anand worked over 7 years as a Director of Pharmaceutical Development Services at WuXi AppTec, Shanghai. In this role he was involved in building the formulation development team and infrastructure to support various dosage form development and pilot scale manufacturing. He also worked with over 35 global clients and over 120 projects to support various stages of clinical development. He was involved as a key SME for successful MPA (EU), US-FDA and C-FDA site inspections for GMP. He was also involved in successfully implementing several key technology platforms including microdoser, hot melt extrusion (HME), bilayer tableting, spray drying etc. He has received “Best team management” award in the year 2013. He is a recipient of several prestigious awards.

Pharmaceutical development focused on poorly soluble compounds as well as successful pharmaceutical project management and contributes in overall CMC development.

Likun got his Bachelor’s degree in Biomedical Devices and PhD in Industry Pharmacy with focus on PAT, imaging, pelletization and coating process. Likun Joined Johnson & Johnson Pharmaceutical Research & Development (Belgium Site) in 2011 and act as scientist to develop and manage automated screening platforms for early development. In 2014, Likun became senior scientist and preformation group leader for automated screening and early development. In 2015, Likun joined Jiangsu Hengrui Medical co. as NanJing R&D site director and returned to China. Hengrui Nanjing R&D site is responsible for preformuation & early development for NMEs, formulation innovation for generics as well as external collaborations and innovation with Universities and research Institutes.

Preformulation & early development, Polymorphism & Salt, Enabling formulation & Processing of small molecules (Amorphous Solid Dispersion, Nano-suspensions, Lipid system), High throughput screening, Biopharmaceutics & PBPK Modeling, Material Characterizaiton & Physical Stability, Controlled Release formulation development, Chemometrics & PAT, Fundamental Understanding of physical stability

Dr. Jinming Gu obtained his Ph.D. degree in Molecular Biology from Vanderbilt University. He then joined Dana-Farber Cancer Institute/Harvard Medical School for a postdoctoral training in oncology. Dr. Gu started his industry career at Merrimack Pharmaceutical, Inc., where he worked on MM111, a bispecific antibody currently in Phase 2 clinical trial. He then joined Abbott Laboratories. Since joining Abbott/Abbvie, he has been leading/working on multiple mAb, ADC, and bispecific antibody programs, including ABT-806, ABT-414, and ABT-165 etc. Dr. Gu is currently the Executive Director of Biologics Discovery at Shanghai Hengrui Pharmaceutical Co., Ltd., a leading innovative pharmaceutical company in China.

Research Interest: Pharmaceutical R&D; Biologics Drug Discovery and Development, Cancer Immunotherapy, Biosimilar, Biobetter.

Harikrishna Tumma has done his PhD from Bangalore University, Bangalore, India and MSc from Osmania University, Hyderabad, India. He brings over 25 years of rich experience in Pharmaceutical industries in the area of process design & development for the new chemical entities and generic APIs. He worked with AstraZeneca, India over 18 years as a management role in the pharmaceutical development and prior to this he worked with Lupin India Ltd for about 7 years. He is specialized in developing the novel, commercially feasible synthetic routes for new chemical entities and non-infringing routes for generic APIs. He is well versed with good laboratory practices including route design, process design & process understanding through statistical approach (design of experiments), process safety, behavioural SHE, scale-up through the process engineering, modern analytical techniques for chemical reaction progress, etc., He has published 18 articles within AstraZeneca Global Process R&D, 4 papers in the international journals and inventor for 6 patents. At present Dr.Hari is working as Executive Director–Process Chemistry & Manufacturing at Pharmaron Beijing Ltd Co., China and managing scientific staff of ca 40-50 including PhD, MSc, BS and engineers.

Process design & Development

Rick Panicucci joined WuXi AppTec in February 2015 as the Vice President of Pharmaceutical Development Services. In this capacity, Rick provides scientific leadership for 160 scientists in Developability, Formulation Development, and GMP Manufacturing and is responsible for the execution of all Parenteral and Oral dosage form programs. He also maintains key client relationships and assesses new technologies through partnering or internal M&A capacity building. In addition to his position at WuXi, Rick currently serves as an Adjunct Professor at Massachusetts College of Pharmacy. Prior to WuXi, Rick was the Global Head of Chemical and Pharmaceutical Profiling (CPP) at Novartis from 2004 to 2015. His responsibilities included analytics, solid state chemistry and formulation development of all small molecule therapeutics in early development. He also helped develop novel drug delivery technologies for small molecules and large molecules including siRNA. Rick has also led groups in Formulation and Research and Development at Vertex Pharmaceuticals, Symbollon Pharmaceuticals, Biogen, and Bausch & Lomb.

Rick received his Ph.D. in Physical Organic Chemistry from the University of Toronto and had two post-doctoral fellowships at University of California at Santa Barbara and the Ontario Cancer Institute. Rick has written 33 publications on Formulations, Drug Delivery, and Drug Discovery.

Peng Li In 1950 graduated from Shanghai first Medical College (Shanghai Medical College of Fudan University), Worked in Department Physiology from 1955-1999. Chair of this Department for 10 years. 1983-84 went to University of Birmingham, UK to learn electrophysiology & have studied over 55 years about electro acupuncture (EA) effect on cardiovascular diseases. Now he worked in the School of Medicine at UC Irvine & has examined the underlying mechanisms of EA with several animal models. Licensed to perform acupuncture in California, investigate the effects of EA in hypertensive patients. He have published over 153 articles and organized five international symposiums.

The use of acupuncture and traditional Chinese medicine to alleviate symptoms of disease, effect and mechanism of acupuncture and moxibustion and like to study TCM scientifically.

Experienced Pharmaceutical professional with proven track record of driving products from concept to development with an emphasis on delivery-enhanced biologics and small molecular drug products; innovations directly led to the launch of a commercial product, and established the development projects for clinical trials.

R&D Innovation, Product Development

Dr. O.L. Shanmugasundaram is working as Professor in the Department of Textile Technology at K.S. Rangasamy College of Technology, India. He obtained his B.Tech. degree in Textile Technology in 2000 from Bannari Amman Institute of Technology, India. He has qualified in the GATE 2003 Examination with 83.21 percentile score. He did his M.Tech. degree in Textile Technology at the Alagappa College of Technology, Anna University, Chennai. He has received his Doctoral degree in Medical Textiles in 2011 from Anna University. He published 10 research papers in refereed International and National journals. He has to his credit 12 papers presented in International Conferences and 4 others in National Conferences. He is an Editorial Advisory Board Member in Textile Review Journal, Textiles and Light Industrial Science & Technology, Indian Journal of Applied Engineering Research, International Journal of Applied Research on Textile, Journal of Textile Science & Engineering. He is acting as Reviewer of Manuscripts in the Journal of Applied Polymer Science, Indian Journal of Fibre & Textile Research, Research Journal of Textile & Apparel, Textile Research Journal, Fibres & Polymers, Natural Fibres and Journal of Industrial Textiles.

Wound dressing, Biopolymers/fibers, Development of Hygiene Textiles, Sutures, Bio-Textiles, Medical Textiles, Technical Textiles, Textile Chemical Processing and Fibre Science & Technology.

Dr. Abdulmohsen H. Alrohaimi graduated from Tufts University Boston USA in the area of Pharmacogenetics. He joined the Saudi Food and Drug Authority (SFDA) as an executive director and he pressed successfully for the creation of the infrastructure for clinical trial in the kingdom. He contributed to SFDA all his skill and expertise and initiated many educational awareness programs for the community development. He chairs many scientific and research committees. He has to his credit two books and several research papers in various highly indexed journals. His priorities have been to mobilize world thought leaders around a set of new global challenges, from climate change and economic upheaval to pandemics and increasing pressures involving food, energy and water, with a special emphasis on Africa and the Middle East and the new Global Strategy on Women’s and Children’s Health. Today, he is holding position of Dean in the School of Pharmacy, Shaqra University.

He is an international speaker and his area of interest is Nanomedicine, Pharmacogenetics Biotechnology and Stem cell techniques.

Prof. Sinerik Ayrapetyan has completed his Ph.D in Cell Biophysics in the Institute of Physiology of Ukraine Academy of Sciences, Kiev. He is the head and coordinator of Research Council of Life Sciences International Postgraduate Educational Center, UNESCO Chair, Yerevan, Armenia. His current research interest is “Intracellular Signaling System in Norm and Pathology”. On this subject he has published 7 international books and 115 papers. He is a member of the board of associate editors for the journals: "Electromagnetic Biology and Medicine", "Journal of International Dental and Medical Research", “ISRN Biophysics”, and a member of editorial board of the journals: “Advances in Life Sciences", “Bioavailability and Bioequivalence”, “Applied Pharmacy”, “European Journal of Biophysics”, “Biochimica et Biophysica Acta”. He is a member of International Coordination Council of WHO and number of professional international societies.

Biophysics, Neuroscience

Duc P. Do, Ph.D. is an associate professor of pharmaceutical sciences (pharmaceutics) at Chicago State University College of Pharmacy (CSU-COP). Prior to joining CSU-COP, he was an assistant professor of pharmaceutical sciences at Lake Erie College of Osteopathic Medicine (LECOM), School of Pharmacy. Dr. Do has received awards in recognition of his teaching, research and service. Dr. Do received his B.S. from the University of Georgia and Ph.D. in pharmaceutical sciences (pharmaceutics) from Mercer University, College of Pharmacy & Health Sciences. His research interests are in the areas of cancer epigenetics, drug delivery systems, dosage form formulation, microencapsulation technology, and pharmaceutical compounding. Dr. Do has over 60 publications and presentations. Currently, he serves as a copyeditor for European Journal of Chemistry, as a member of the Editorial Board for thirteen journals and as a reviewer for over fourteen scientific journals. Additionally, Dr. Do has served as an abstract and grant reviewer for several organizations. In regards to teaching, he has taught pharmaceutics courses, including advanced drug delivery systems, pharmaceutical dosage forms, pharmaceutical compounding and pharmacokinetics. Dr. Do is a member of several scientific and professional organizations, including the American Association of Colleges of Pharmacy (AACP), the American Association of Pharmaceutical Scientists (AAPS) and the Regulatory Affairs Professional Society (RAPS).

Cancer Epigenetics, Drug Delivery Systems, Dosage Form Formulation, Microencapsulation Technology, and Pharmaceutical Compounding

Fawzi’s core research has been geared mainly towards drug discovery from natural products. In this respect has been active in documenting the traditional knowledge pertaining to the use of medicinal herbs and food plants. Also one of Fawzi’s main interests is to develop standard extracts of locally available indigenous bio-products geared towards novel applications of traditional underutilised food plants having significant therapeutic and nutritional properties in an endeavour to address future food security issues and global sustainability. He is currently the editor of several peer reviewed intentional journal and has authored around 80 publications.

Indigenous Bio-Products Therapeutic and Nutritional

Dr. Ibrahim Al-Khars is working as Business Development Manager and Senior Consultant for People & Business Development Center. Dr. Al-Khars has a Master in Business Administration specialized in International Business from the University of Florida, USA and special diploma degree in new venture creation from the same university. He received a Bachelor degree in Pharmaceutical Science from King Saud University, Riyadh, Saudi Arabia with honor and Master Degree in Clinical Pharmacy from the same university. His academic history includes a Specialty Residency in Pharmacy Practice Management at Detroit Receiving Hospital and Wayne State University, Detroit, Michigan in addition to be certified as Six Sigma Championship. Dr. Al-Khars had many positions starting as pharmacist and ended up as the vice dean for Mohammad Almana Colleges for Health Sciences and director of Almana Health Institute, Khobar, Saudi Arabia. In addition to his work, Dr. Al-Khars is the president of Al-Ahssa pharmacy club, Saudi Pharmaceutical Society.

His research interests include health care quality improvement, the economic evaluation of treatment strategies, health care educational system and technologies, and methods for the economic evaluation of health care programs. In addition to his teaching and management activities, Dr. Al-Khars has conducted many presentations, executive seminars and management development programs in different countries including Saudi Arabia, USA, Lebanon, Oman, and United Arab Emirates.

Dr. D.Nagasamy Venkatesh is Assistant Professor at Department of Pharmaceutics, JSS College of Pharmacy, Udhagamandalam. India. Dr. D.Nagasamy Venkatesh is interested in developing certain nanobased drug delivery systems for antiviral and anticancer drugs. His research is also involved in developing sustained/controlled drug delivery systems for certain drugs and analytical and bio-analytical method development for drugs. He serves as a reviewer of more than 25 peer reviewed journals including AAPS, Carbohydrate polymer, Indian Journal of Pharmaceutical Sciences. He serves editorial board member for more than 20 international journals. Dr. D.Nagasamy Venkatesh has authored more than 50 peer-reviewed publications. He has received two awards for his presentations/publications in a national level seminar.

Nano based drug delivery systems for antiviral and anticancer drugs, developing sustained/controlled drug delivery systems for certain drugs, dissolution enhancement of certain drugs by solid dispersion techniques analytical and bio-analytical method development for drugs.